Cardiologists question FDA tips about genetic screening before taking Plavix Which antiplatelet medication is most beneficial after a coronary stent? The potential and pricey life-or-death query lingers after the majority of the 600, 000 angioplasties performed every full year in the United States. The response may lie in your genes, but professional cardiovascular societies and several working cardiologists question the U.S ed drugs . Food and Drug Administration's recent recommendation that individuals undergo genetic testing before taking Plavix . MULTIMEDIA ALERT: Audio bites of an interview with Dr. Pereira, research principal investigator, can be found on the Mayo Clinic News Network. The Tailored Antiplatelet Therapy to reduce Outcomes after Percutaneous Coronary Intervention Research, launched this summer by the guts for Individualized Medication and the Division of Cardiovascular Illnesses at Mayo Clinic, examines whether prescribing heart medication based on a patient's CYP2C19 genotype shall assist in preventing heart attack, stroke, unstable angina, and cardiovascular death in individuals who undergo percutaneous coronary intervention, called angioplasty commonly.
This small-sized vertebral balloon now allows interventional radiologists and backbone surgeons to repair vertebral compression fractures that have been historically even more difficult to treat because of their size and location in the spine, including smaller sized vertebra. The 11-gauge vertebral balloon is certainly inserted through a cannula that’s 17 % smaller sized and a balloon shaft that’s 25 % smaller sized than any other vertebral balloon in the marketplace. This design miniaturization helps to make the procedure much less invasive for individuals without compromising the medical efficacy of the device because it still meets the pressure and volume requirements of legacy vertebral balloons.